PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 53% · Mixed 28% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 25 days · Based on 343 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 68% · Mixed 16% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 168 repeat reporters
Published sources linked on the Cagrilintide and IGF-1 LR3 wiki pages.
PubMed
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024
PubMed
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025
PubMed
Baxter RC. Endocr Rev. 2011
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025
PubMed
Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025